Transforming the Treatment of Non-alcoholic Steatohepatitis
Pursuing novel therapeutics targeting NASH
Madrigal is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Our most advanced clinical candidate, resmetirom, is currently being studied for the treatment of patients with NASH with liver fibrosis and NASH with compensated cirrhosis.
